Last reviewed · How we verify

NCT07274956: DIENerveDens

Nerve Fiber Density in DIE Nodules & Pelvic Pain

Completed Last updated 10 December 2025
What this trial tests

trial in Deep Infiltrating Endometriosis, Pelvic Pain, Dysmenorrhea Dyspareunia in 65 participants. Completed in 27 June 2025.

Timeline
1 February 2022
Primary endpoint
27 June 2025
27 June 2025

Quick facts

Lead sponsorBaşakşehir Çam & Sakura City Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment65
Start date1 February 2022
Primary completion27 June 2025
Estimated completion27 June 2025
Sites2 locations across Turkey (Türkiye)

Conditions studied

Sponsor

Başakşehir Çam & Sakura City Hospital

Who can join

Adults 18 to 55, female only, with Deep Infiltrating Endometriosis, Pelvic Pain, Dysmenorrhea Dyspareunia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Deep infiltrating endometriosis (DIE) is a highly symptomatic form of endometriosis linked to severe dysmenorrhea, dyspareunia, dyschezia, dysuria, and chronic pelvic pain. Histologic studies suggest abundant neural elements in DIE nodules, but the relationship between nodule-level nerve fiber density and patient-reported pelvic pain remains insufficiently defined. This retrospective, cross-sectional study with prospective pathology re-review evaluates whether nerve fiber density in surgically excised DIE nodules correlates with pain severity and location. Women aged 18-55 who underwent surgery for DIE after inadequate response to medical therapy are included. Clinical data (demographics, gynecologic history, prior treatments) and standardized pain scores (VAS for pain domains) are abstracted from records. Archived blocks are recut; sections are stained with H\&E and immunolabeled (e.g., SOX-10) to quantify neural profiles and derive a nerve fiber density metric per nodule. Primary endpoint: association between nerve fiber density and pain intensity/localization. Secondary endpoints: relationships with lesion site/depth and other clinicopathologic variables; exploratory discrimination of severe-pain phenotypes. Statistics (χ²/Fisher, t/Mann-Whitney, Kaplan-Meier/Cox if applicable) use two-sided p\<0.05. This minimal-risk study uses existing records and archived tissue only; findings may inform counseling, nerve-sparing surgical planning, and future biomarker-driven, response-adapted trials.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Başakşehir Çam & Sakura City Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07274956.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing